Table 3.
Student's t-test (paired) analyses for comparison of the scores obtained from the Aflapin and 5-Loxin groups at day 90
| n | Baseline | Day 90 | 95% CI (versus placebo) | p | |||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||||
| Visual analogue scale score | |||||||
| Placebo | 19 | 47.7 | 6.5 | 38.3 | 9.0 | 34.0, 42.7 | 0.0013 |
| 5-Loxin 100 mg/day | 19 | 48.2 | 6.1 | 26.2 | 16.5 | 18.2, 34.1 | <0.0001 |
| Aflapin 100 mg/day | 19 | 47.7 | 7.3 | 20.2 | 12.3 | 14.2, 26.1 | <0.0001 |
| Lequesne's Functional Index | |||||||
| Placebo | 19 | 12.3 | 2.8 | 10.9 | 3.0 | 9.4, 12.3 | 0.0496 |
| 5-Loxin 100 mg/day | 19 | 12.4 | 2.6 | 8.9 | 3.7 | 7.1, 10.7 | <0.0001 |
| Aflapin 100 mg/day | 19 | 12.0 | 2.4 | 7.0 | 2.6 | 7.1, 9.6 | <0.0001 |
| WOMAC pain subscale | |||||||
| Placebo | 19 | 44.7 | 11.5 | 36.3 | 10.5 | 31.2, 41.4 | 0.0021 |
| 5-Loxin 100 mg/day | 19 | 46.1 | 7.6 | 25.3 | 17.2 | 17.0, 33.6 | <0.0001 |
| Aflapin 100 mg/day | 19 | 45.0 | 13.3 | 13.9 | 8.3 | 10.0, 17.9 | <0.0001 |
| WOMAC stiffness subscale | |||||||
| Placebo | 19 | 39.5 | 11.2 | 29.6 | 9.5 | 25.0, 34.2 p | 0.0059 |
| 5-Loxin 100 mg/day | 19 | 39.5 | 11.2 | 17.1 | 16.8 | 9.0, 25.2 | 0.0001 |
| Aflapin 100 mg/day | 19 | 39.5 | 13.3 | 11.8 | 12.8 | 5.7, 18.0 | <0.0001 |
| WOMAC function subscale | |||||||
| Placebo | 19 | 42.0 | 10.3 | 32.0 | 10.8 | 26.8, 37.2 | 0.0025 |
| 5-Loxin 100 mg/day | 19 | 43.1 | 7.8 | 25.2 | 15.0 | 17.9, 32.4 | <0.0001 |
| Aflapin 100 mg/day | 19 | 42.0 | 8.4 | 16.2 | 8.1 | 12.3, 20,1 | <0.0001 |
CI, confidence interval; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.